07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

Cadiogen, Audentes Therapeutics deal

Audentes acquired fellow rare disease company Cardiogen for an undisclosed amount. Audentes gains AT003 (formerly CASQ2-CPVT ), a preclinical adeno-associated virus (AAV) vector-based therapy that delivers calsequestrin 2 (CASQ2) to cardiomyocytes to treat catecholaminergic polymorphic...